Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team

To compare the antiviral activity, effect on CD4 cell count, and tolerability of didanosine (ddI) administered once daily and twice daily in HIV-1-infected patients receiving ddI with stavudine or zidovudine, with or without a protease inhibitor. The study was designed to demonstrate that once-daily...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2000-08, Vol.24 (5), p.418-424
Hauptverfasser:	Kazatchkine, M D, Van, P N, Costagliola, D, Mohammed, A S, Ledeine, J M, Troccaz, M, Belec, L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS/HIV Anti-HIV Agents - administration & dosage Didanosine - administration & dosage Drug Administration Schedule Drug Therapy, Combination Female HIV Infections - drug therapy HIV Reverse Transcriptase - genetics HIV-1 - enzymology HIV-1 - genetics Humans Male Middle Aged Mutation Reverse Transcriptase Inhibitors - administration & dosage RNA, Viral - blood Stavudine - administration & dosage Treatment Outcome Zidovudine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To compare the antiviral activity, effect on CD4 cell count, and tolerability of didanosine (ddI) administered once daily and twice daily in HIV-1-infected patients receiving ddI with stavudine or zidovudine, with or without a protease inhibitor. The study was designed to demonstrate that once-daily dosing of ddI was not inferior to twice-daily dosing. Randomized, open-label, multicenter, two-arm study. 121 HIV-1-infected adults on a stable regimen including ddI (twice daily) during the previous 3 months with a stable viral load
ISSN:	1525-4135